Compare BVC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVC | NUVB |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | Hong Kong | United States |
| Employees | 6 | 307 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | BVC | NUVB |
|---|---|---|
| Price | $10.61 | $4.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 9.5K | ★ 4.2M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $1.57 |
| 52 Week High | $15.00 | $9.75 |
| Indicator | BVC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 49.62 |
| Support Level | $8.50 | $4.07 |
| Resistance Level | $11.54 | $5.16 |
| Average True Range (ATR) | 1.17 | 0.36 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 65.99 | 31.00 |
BitVentures Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. The Company is developing technology businesses in verticals including e-commerce, digital assets, consumer healthcare, and other areas of consumer.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.